期刊
NEURAL REGENERATION RESEARCH
卷 13, 期 3, 页码 373-385出版社
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/1673-5374.228711
关键词
cerebral ischemia; melatonin; resveratrol; protein kinase C; pifithrin-alpha; fatty acids; sympathetic nervous system; neuromodulation therapy; traditional Chinese therapies; stem cell
资金
- National Institutes of Health/National Institute of Neurological Disorders and Stroke [1R01NS096225-01A1]
- American Heart Association grants [AHA-13SDG1395001413, AHA-17GRNT33660336, AHA-17POST33660174]
- Louisiana State University Grant in Aid research council
- Malcolm Feist Cardiovascular Research Fellowship
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS096225] Funding Source: NIH RePORTER
Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies again st stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据